BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 30146269)

  • 1. Newborn blood spot screening for cystic fibrosis with a four-step screening strategy in the Netherlands.
    Dankert-Roelse JE; Bouva MJ; Jakobs BS; Janssens HM; de Winter-de Groot KM; Schönbeck Y; Gille JJP; Gulmans VAM; Verschoof-Puite RK; Schielen PCJI; Verkerk PH
    J Cyst Fibros; 2019 Jan; 18(1):54-63. PubMed ID: 30146269
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cystic fibrosis newborn screening in Denmark: Experience from the first 2 years.
    Skov M; Baekvad-Hansen M; Hougaard DM; Skogstrand K; Lund AM; Pressler T; Olesen HV; Duno M
    Pediatr Pulmonol; 2020 Feb; 55(2):549-555. PubMed ID: 31682332
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population-based newborn screening for genetic disorders when multiple mutation DNA testing is incorporated: a cystic fibrosis newborn screening model demonstrating increased sensitivity but more carrier detections.
    Comeau AM; Parad RB; Dorkin HL; Dovey M; Gerstle R; Haver K; Lapey A; O'Sullivan BP; Waltz DA; Zwerdling RG; Eaton RB
    Pediatrics; 2004 Jun; 113(6):1573-81. PubMed ID: 15173476
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A model-based economic evaluation of four newborn screening strategies for cystic fibrosis in Flanders, Belgium.
    Schmidt M; Werbrouck A; Verhaeghe N; De Wachter E; Simoens S; Annemans L; Putman K
    Acta Clin Belg; 2020 Jun; 75(3):212-220. PubMed ID: 31007159
    [No Abstract]   [Full Text] [Related]  

  • 5. Diagnosing cystic fibrosis in newborn screening in Poland - 15 years of experience.
    Sands D; Zybert K; Mierzejewska E; Ołtarzewski M
    Dev Period Med; 2015; 19(1):16-24. PubMed ID: 26003066
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimization of the French cystic fibrosis newborn screening programme by a centralized tracking process.
    Munck A; Delmas D; Audrézet MP; Lemonnier L; Cheillan D; Roussey M
    J Med Screen; 2018 Mar; 25(1):6-12. PubMed ID: 28454512
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Final results of the southwest German pilot study on cystic fibrosis newborn screening - Evaluation of an IRT/PAP protocol with IRT-dependent safety net.
    Sommerburg O; Stahl M; Hämmerling S; Gramer G; Muckenthaler MU; Okun J; Kohlmüller D; Happich M; Kulozik AE; Mall MA; Hoffmann GF
    J Cyst Fibros; 2022 May; 21(3):422-433. PubMed ID: 34764021
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunoreactive trypsinogen levels in newborn screened infants with an inconclusive diagnosis of cystic fibrosis.
    Ooi CY; Sutherland R; Castellani C; Keenan K; Boland M; Reisman J; Bjornson C; Chilvers MA; van Wylick R; Kent S; Price A; Mateos-Corral D; Hughes D; Solomon M; Zuberbuhler P; Brusky J; Durie PR; Ratjen F; Gonska T
    BMC Pediatr; 2019 Oct; 19(1):369. PubMed ID: 31640630
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Initial evaluation of a biochemical cystic fibrosis newborn screening by sequential analysis of immunoreactive trypsinogen and pancreatitis-associated protein (IRT/PAP) as a strategy that does not involve DNA testing in a Northern European population.
    Sommerburg O; Lindner M; Muckenthaler M; Kohlmueller D; Leible S; Feneberg R; Kulozik AE; Mall MA; Hoffmann GF
    J Inherit Metab Dis; 2010 Oct; 33(Suppl 2):S263-71. PubMed ID: 20714932
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of newborn screening for cystic fibrosis determined with real-life data.
    van der Ploeg CP; van den Akker-van Marle ME; Vernooij-van Langen AM; Elvers LH; Gille JJ; Verkerk PH; Dankert-Roelse JE;
    J Cyst Fibros; 2015 Mar; 14(2):194-202. PubMed ID: 25213034
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of different IRT-PAP protocols to screen newborns for cystic fibrosis in three central European populations.
    Sommerburg O; Krulisova V; Hammermann J; Lindner M; Stahl M; Muckenthaler M; Kohlmueller D; Happich M; Kulozik AE; Votava F; Balascakova M; Skalicka V; Stopsack M; Gahr M; Macek M; Mall MA; Hoffmann GF
    J Cyst Fibros; 2014 Jan; 13(1):15-23. PubMed ID: 23891278
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improving the Sensitivity and Positive Predictive Value in a Cystic Fibrosis Newborn Screening Program Using a Repeat Immunoreactive Trypsinogen and Genetic Analysis.
    Sontag MK; Lee R; Wright D; Freedenberg D; Sagel SD
    J Pediatr; 2016 Aug; 175():150-158.e1. PubMed ID: 27131402
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospective and parallel assessments of cystic fibrosis newborn screening protocols in the Czech Republic: IRT/DNA/IRT versus IRT/PAP and IRT/PAP/DNA.
    Krulišová V; Balaščaková M; Skalická V; Piskáčková T; Holubová A; Paděrová J; Křenková P; Dvořáková L; Zemková D; Kračmar P; Chovancová B; Vávrová V; Stambergová A; Votava F; Macek M
    Eur J Pediatr; 2012 Aug; 171(8):1223-9. PubMed ID: 22581207
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A survey of the prevalence, management and outcome of infants with an inconclusive diagnosis following newborn bloodspot screening for cystic fibrosis (CRMS/CFSPID) in six Italian centres.
    Terlizzi V; Claut L; Tosco A; Colombo C; Raia V; Fabrizzi B; Lucarelli M; Angeloni A; Cimino G; Castaldo A; Marsiglio L; Timpano S; Cirilli N; Moroni L; Festini F; Piccinini P; Zavataro L; Bonomi P; Taccetti G; Southern KW; Padoan R
    J Cyst Fibros; 2021 Sep; 20(5):828-834. PubMed ID: 33883100
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cystic Fibrosis Transmembrane Conductance Regulator-Related Metabolic Syndrome and Cystic Fibrosis Screen Positive, Inconclusive Diagnosis.
    Ren CL; Borowitz DS; Gonska T; Howenstine MS; Levy H; Massie J; Milla C; Munck A; Southern KW
    J Pediatr; 2017 Feb; 181S():S45-S51.e1. PubMed ID: 28129812
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A survey of newborn screening for cystic fibrosis in Europe.
    Southern KW; Munck A; Pollitt R; Travert G; Zanolla L; Dankert-Roelse J; Castellani C;
    J Cyst Fibros; 2007 Jan; 6(1):57-65. PubMed ID: 16870510
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Evaluation of 47,213 infants in neonatal screening for cystic fibrosis, using pancreatitis-associated protein and immunoreactive trypsinogen assays].
    Barthellemy S; Maurin N; Roussey M; Férec C; Murolo S; Berthézène P; Iovanna JL; Dagorn JC; Sarles J
    Arch Pediatr; 2001 Mar; 8(3):275-81. PubMed ID: 11270251
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Screening for cystic fibrosis in newborn infants: results of a pilot programme based on a two tier protocol (IRT/DNA/IRT) in the Italian population.
    Corbetta C; Seia M; Bassotti A; Ambrosioni A; Giunta A; Padoan R
    J Med Screen; 2002; 9(2):60-3. PubMed ID: 12133923
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel strategies in newborn screening for cystic fibrosis: a prospective controlled study.
    Vernooij-van Langen AM; Loeber JG; Elvers B; Triepels RH; Gille JJ; Van der Ploeg CP; Reijntjens S; Dompeling E; Dankert-Roelse JE;
    Thorax; 2012 Apr; 67(4):289-95. PubMed ID: 22271776
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The expansion and performance of national newborn screening programmes for cystic fibrosis in Europe.
    Barben J; Castellani C; Dankert-Roelse J; Gartner S; Kashirskaya N; Linnane B; Mayell S; Munck A; Sands D; Sommerburg O; Pybus S; Winters V; Southern KW
    J Cyst Fibros; 2017 Mar; 16(2):207-213. PubMed ID: 28043799
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.